<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="719">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652115</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003203</org_study_id>
    <nct_id>NCT04652115</nct_id>
  </id_info>
  <brief_title>A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19</brief_title>
  <acronym>DF in COVID19</acronym>
  <official_title>A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19&#xD;
      pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, two-cohort, phase 2 pilot study that will evaluate&#xD;
      the safety and efficacy of defibrotide in clinically severe COVID-19. The defibrotide dose&#xD;
      that is approved by the FDA for the treatment of post-HSCT VOD/SOS (6.25 mg/kg IV q6 hours)&#xD;
      will be used.&#xD;
&#xD;
      Cohort 1 will consist of patients with COVID-19 pneumonia confirmed by PCR and radiography,&#xD;
      who are hospitalized with an oxygen requirement (either supplemental O2 or mechanical&#xD;
      ventilation), are not on therapeutic dose anticoagulation, and require no more than one&#xD;
      vasopressive agent to maintain hemodynamic stability. Cohort 2 will consist of patients with&#xD;
      COVID-19 pneumonia confirmed by PCR and radiography, who are hospitalized in the ICU and are&#xD;
      at elevated risk of hemorrhage and/or hypotension, the former defined as a requirement for&#xD;
      therapeutic dose anticoagulation for active thrombosis, ECMO, or CRRT, and the latter defined&#xD;
      as a requirement for two vasopressive agents to maintain hemodynamic stability.&#xD;
&#xD;
      In cohort 2 only, a 6+6 dose de-escalation design will be utilized, in which if 2 of 6 DLTs&#xD;
      are experienced in the first 6 subjects, the dose will be reduced from 6.25 mg/kg IV q6hrs to&#xD;
      10mg/kg/d CIVI. If there are 0 or 1 DLTs in the first 6 subjects at the FDA-approved dose,&#xD;
      another 6 subjects will be enrolled at the same dose. Grade 3/4 hemorrhage and significant&#xD;
      new hypotension will be considered DLT's.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single arm, two cohort clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of adverse event of special interest (bleeding and hypotension)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The rate of adverse event of special interest (bleeding and hypotension)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Defibrotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Defibrotide IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>Deibrotide via IV</description>
    <arm_group_label>Defibrotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years.&#xD;
&#xD;
          2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.&#xD;
&#xD;
          3. Radiographic evidence of bilateral pulmonary infiltrates.&#xD;
&#xD;
          4. A life expectancy of at least 24 hours.&#xD;
&#xD;
          5. Score of 4-7 on the WHO ordinal scale.&#xD;
&#xD;
          6. Prophylactic dose anticoagulation is allowed for enrollment into cohort 1. Therapeutic&#xD;
             dose anticoagulation for active thrombosis, ECMO, and/or continuous renal replacement&#xD;
             therapy (CRRT) is allowed for enrollment into cohort 2 if there is no evidence of&#xD;
             bleeding after at least 24 hours of anticoagulation.&#xD;
&#xD;
          7. Patient or surrogate able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant acute bleeding.&#xD;
&#xD;
          2. Concomitant use of thrombolytic therapy (e.g. t-PA).&#xD;
&#xD;
          3. Hemodynamic instability, defined as a requirement for &gt;1 vasopressor agent for&#xD;
             enrollment into cohort 1, and a requirement for &gt;2 vasopressor agents for enrollment&#xD;
             into cohort 2&#xD;
&#xD;
          4. Known allergy or hypersensitivity to DF.&#xD;
&#xD;
          5. Pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul G Richardson, MD</last_name>
      <email>Paul_Richardson@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Paul G Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Paul G. Richardson, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

